Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

NuCana PLC

NCNA ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: N/A

Last Close

$1.01

▼ -5.61%

Market Cap $4.35M · Vol 6.20K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$4.35M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

41.21

Momentum

Beta

2.36

vs Market

52W High

$4.50

77.56% below

52W Low

$0.95

6.32% above

Volume

6.20K

Avg 23.28K

P/B

91.43

Price-to-book

ROE

N/A

Return on equity

Free Float

100.00%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, NuCana PLC (NCNA) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does NCNA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+2.51%

-25.19%

-19.84%

-52.58%

YTD

-71.94%

-72.78%

-99.96%

-99.99%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-39,547,041.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-136.84% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	91.43
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	21.55B

Technical Indicators

50-Day SMA	$1.24
200-Day SMA	$1.75
RSI (14)	41.21
Beta	2.36
52-Week High	$4.50
52-Week Low	$0.95

Volume Today	6.20K
Avg Daily Volume (30D)	23.28K
Relative Volume	0.27x
Volatility (10D)	56.48
Volatility (30D)	71.02
Free Float	100.00%

Analyst Consensus

N/A

Current Price $1.01

Mean Target N/A

52W Low$0.95 52W High$4.50

Current

Target

$0.95 $4.50

Current Analyst target

· 0 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00HMJNNK8

ISINUS67022C3043

CountryUK

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -2.98% ARGX.BR argenx SE +0.35% ARGX argenx SE -0.55% GMAB.CO Genmab A/S +3.27% GMAB Genmab A/S +1.01%

Company Profile

NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.